coumarin-SAHA | CAS 1260635-77-5

Catalog Number	A18-0018
Category	Fluorescent Enzyme Substrates
Molecular Formula	C18H22N2O5
Molecular Weight	346.4

Inquiry

* Please be kindly noted products are not for therapeutic use. We do not sell to patients.

Worldwide Delivery
Quality Assurance
24/7 Customer Service

Product Introduction

Histone deacetylase inhibitor conjugated fluorescent probe for epigenetic research. Enables visualization of HDAC activity in live cells.

Chemical Information
Product Specification
Application

Synonyms	Coumarin-Suberoylanilide Hydroxamic Acid; N1-hydroxy-N8-(4-methyl-2-oxo-2H-chromen-7-yl)-octanediamide
Purity	≥98%
Canonical SMILES	CC1=CC(=O)OC2=C1C=CC(=C2)NC(=O)CCCCCCC(=O)NO
InChI	InChI=1S/C18H22N2O5/c1-12-10-18(23)25-15-11-13(8-9-14(12)15)19-16(21)6-4-2-3-5-7-17(22)20-24/h8-11,24H,2-7H2,1H3,(H,19,21)(H,20,22)
InChIKey	YSRCADVJNRJJAV-UHFFFAOYSA-N
Appearance	Solid Powder

Excitation	325 nm
Emission	400 nm
Storage	Store at -20°C

Coumarin-SAHA, a hybrid molecule merging coumarin and SAHA (suberoylanilide hydroxamic acid), presents diverse applications in clinical and research domains.

Cancer Therapy: Investigated as a prospective anticancer agent, Coumarin-SAHA exhibits a dual mechanism of action. The coumarin moiety exerts cytotoxic effects complemented by SAHA’s role as a histone deacetylase (HDAC) inhibitor, inducing apoptosis in cancer cells. This hybrid molecule signifies a synergistic approach to combat various cancers, bolstering efficacy and specificity simultaneously.

Epigenetic Research: Emphasizing the HDAC inhibitory aspect, the SAHA component of Coumarin-SAHA proves invaluable for probing epigenetic alterations within cells. By thwarting HDAC enzymes, researchers delve into histone acetylation’s impact on gene expression and chromatin remodeling. Leveraging Coumarin’s fluorescence attributes enables dual utility for cellular imaging, enriching epigenetic inquiries.

Neurodegenerative Disease Study: Within the realm of neurodegenerative disorder investigation, Coumarin-SAHA showcases promise for conditions like Alzheimer’s and Parkinson’s. HDAC inhibition holds potential for modulating gene expression linked to neuroprotection and cognitive faculties. Coumarin’s blood-brain barrier transversal ability enhances compound delivery to neural tissues, augmenting neurodegenerative disease research.

Drug Screening: Coumarin-SAHA’s utility extends to high-throughput screening assays, facilitating the discovery of novel therapeutic agents. The compound’s dual-mode of action and fluorescence properties position it aptly for pinpointing potential histone deacetylase inhibitors and evaluating their impact on cell viability. This application accelerates drug development targeting epigenetic regulators and pivotal cellular processes, propelling pharmaceutical advancements.